Release date: 2024-07-09 17:01:48 Article From: Lucius Laos Recommended: 157
Sotorasib emerges as a groundbreaking targeted therapy for non-small cell lung cancer (NSCLC) individuals carrying KRAS G12C alterations. Sotorasib exerts its therapeutic efficacy by specifically inhibiting the activity of the KRAS G12C mutated protein, thus offering a novel treatment option for patients harboring such genetic alterations.
Sotorasib is divided into original and generic drugs in terms of price. The original variant is manufactured by Amgen in the United States, featuring a dosage of 120mg per capsule, with a package containing 240 capsules priced at approximately 80,155 RMB. Several generic alternatives of Sotorasib are currently available worldwide, such as Everest Medicines, Lucius in Laos, and Bokron in Paraguay. Everest Medicines and Lucius offer packs comprising 56 capsules of 120mg each, priced at around 4,900 RMB and 2,850 RMB respectively. Bokron in Paraguay, on the other hand, presents a package containing 120 capsules of 120mg each, priced at approximately 7,500 RMB per box.
The aforementioned prices serve as a guide, with actual prices contingent upon variables including procurement avenues, policy modifications, and market dynamics. Sotorasib constitutes a pharmacological agent requiring strict adherence to the prescribing physician's directives. Patient compliance with the recommended regimen is vital, as is a comprehensive understanding of the drug's precautions and considerations for use in special patient populations prior to initiation.
Patients should be vigilant regarding the following precautions while utilizing Sotorasib and are advised to seek medical advice promptly in the event of discomfort or apprehension arising from the medication.
Sotorasib is a prescription drug, that necessitates scrupulous adherence to the prescribed regimen outlined by a healthcare professional. Patients are advised against self-modification of dosage or alterations in the administration protocol.
While Sotorasib demonstrates efficacy, it is not devoid of adverse effects. Therefore, individuals must vigilantly monitor their physiological state while utilizing this therapeutic agent and promptly consult medical professionals should they experience any untoward symptoms or irregularities.
In conjunction with pharmacotherapy, patients ought to adhere to a regimen of healthy living, encompassing a balanced diet, regular physical activity, cessation of tobacco use, and moderation in alcohol intake. These lifestyle modifications can synergistically enhance therapeutic outcomes while mitigating untoward effects.
[Warm tips] Patients are encouraged to cultivate a positive and optimistic mindset while undergoing treatment with Sotorasib, adhere closely to the recommendations of their healthcare provider, and endeavor towards a swift convalescence. Additionally, individuals should prioritize dietary vigilance, uphold healthy lifestyle practices, and bolster the body's immune defenses.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: